Chemotherapy

Young children who underwent treatment for brain tumors had lower academic readiness scores than their peers, according to results of a prospective longitudinal trial.

Sacituzumab govitecan-hziy exhibited efficacy as therapy for two traditionally difficult-to-treat populations, according to results of a window-of-opportunity trial.

The addition of comprehensive metastasis-directed radiation therapy to chemotherapy improved outcomes for patients with oligometastatic pancreatic ductal adenocarcinoma, according to results of a randomized phase 2 basket trial.

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

Oregon Health & Science University has implemented a “symptom science” clinical research program designed to mitigate toxicities and improve quality of life for people with cancer.

A randomized phase 3 trial designed to compare two combinations for first-line treatment of lung cancer has been halted after an interim analysis revealed no survival benefit and more toxicity with the experimental regimen.

Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia increasingly receive tisagenlecleucel in earlier settings when they have lower disease burden, according to findings presented at ASCO Annual Meeting.

Many people who experience side effects from cancer treatment wait nearly a month to see a specialist with the necessary expertise.

Chemotherapy-induced changes to the gut microbiome may explain why some patients with cancer experience post-chemotherapy cognitive decline.

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with standard chemoimmunotherapy for certain adults with leukemia, according to a topline data announcement.